WP
FULC icon

Woodline Partners’s Fulcrum Therapeutics FULC Stock Holding History

Woodline Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,793
Closed -$236K – 1078
2026
Q1 		$236K Hold
30,793
– – ﹤0.01% 1016
2025
Q4 		$348K Buy
+30,793
New +$313K ﹤0.01% 945
2025
Q3 		– Sell
-897,617
Closed -$6.18M – 951
2025
Q2 		$6.18M Hold
897,617
– – 0.03% 521
2025
Q1 		$2.59M Sell
897,617
-512,903
-36% -$1.88M 0.02% 627
2024
Q4 		$6.63M Buy
1,410,520
+739,713
+110% +$2.73M 0.04% 429
2024
Q3 		$2.39M Buy
670,807
+169,506
+34% +$1.26M 0.02% 460
2024
Q2 		$3.11M Buy
+501,301
New +$3.8M 0.03% 383
2023
Q3 		– Sell
-596,695
Closed -$1.97M – 643
2023
Q2 		$1.97M Buy
+596,695
New +$1.75M 0.02% 434

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Woodline Partners's FULC Position: Q2 2026 in Review

Woodline Partners sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 30,793 shares — an estimated $236K sold.

Woodline Partners first reported a position in FULC in Q2 2023 and held it in 8 quarters. The position peaked at $6.63M in Q4 2024. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Woodline Partners reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 30,793 Fulcrum Therapeutics shares in Q2 2026, an estimated $236K.
  • Woodline Partners first reported a position in Fulcrum Therapeutics in Q2 2023 and held it in 8 quarters.
  • Woodline Partners's Fulcrum Therapeutics position peaked at $6.63M in Q4 2024.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.